210
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Risk Factors Associated with Methotrexate Intolerance in Rheumatoid Arthritis Patients

ORCID Icon, ORCID Icon, ORCID Icon, , , , , ORCID Icon, ORCID Icon, & ORCID Icon show all
Pages 193-202 | Published online: 07 Sep 2020

References

  • Pincus T, Gibson KA, Castrejón I. Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Joint Dis. 2013;71(Suppl 1):S9–S19.
  • Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007;66(11):1491–1496. doi:10.1136/ard.2006.06925217412740
  • Al-Niaimi F, Cox NH. Methotrexate safety: from prescribing to labelling. Br J Dermatol. 2009;160(6):1345–1346. doi:10.1111/j.1365-2133.2009.09111.x19416263
  • Brunner HI, Johnson AL, Barron AC, et al. Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire. J Clin Rheumatol. 2005;11(4):194–204. doi:10.1097/01.rhu.0000173616.81928.4416357756
  • Chan ESL, Cronstein BN. Mechanisms of action of methotrexate. Bull Hosp Joint Dis. 2013;71(Suppl 1):S5–S8.
  • Fatimah N, Salim B, Nasim A, Hussain K, Gul H, Niazi S. Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire). Clin Rheumatol. 2016;35(5):1341–1345. doi:10.1007/s10067-016-3243-827053094
  • Bulatović M, Heijstek MW, Verkaaik M, et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 2011;63(7):2007–2013. doi:10.1002/art.3036721437879
  • Ćalasan MB, van den Bosch OFC, Creemers MCW, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther. 2013;15(6):R217. doi:10.1186/ar441324345416
  • Albaqami J, Alshalhoub R, Almalag H, et al. Prevalence of methotrexate intolerance among patients with rheumatoid arthritis using the Arabic version of the methotrexate intolerance severity score. Int J Rheum Dis. 2019;22(8):1572–1577. doi:10.1111/1756-185X.1363731245906
  • Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi:10.1002/art.2758420872595
  • von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ. 2007;85(11):867–872. doi:10.2471/BLT.07.04512018038077
  • Malmström V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol. 2017;17(1):60–75. doi:10.1038/nri.2016.12427916980
  • Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Cl. Arthritis Care Res (Hoboken). 2011;63(S11):S14–S36. doi:10.1002/acr.2062122588741
  • Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42(2):107–121. doi:10.2165/00003088-200342020-0000112537512
  • Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet. 1978;3(1):1–13. doi:10.2165/00003088-197803010-00001346283
  • Godfrey C, Sweeney K, Miller K, Hamilton R, Kremer J. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol. 1998;46(4):369–376. doi:10.1046/j.1365-2125.1998.t01-1-00790.x9803986
  • Smedstad L, Kvien T, Mourn T, Vaglum P. Correlates of patients‘ global assessment of arthritis impact: a 2-year study of 216 patients with RA. Scand J Rheumatol. 1997;26(4):259–265. doi:10.3109/030097497091053139310104
  • Al-Malaq HM, Al-Arfaj HF, Al-Arfaj AS. Adverse drug reactions caused by methotrexate in Saudi population. Saudi Pharm J. 2012;20(4):301–305. doi:10.1016/j.jsps.2012.05.00423960804